CLINICAL TRIALS PROFILE FOR MITOZYTREX

All Clinical Trials for MITOZYTREX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01004978 ↗	Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2009-10-28	This randomized phase III trial studies chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride, mitomycin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemoembolization kills tumor cells by carrying drugs directly into blood vessels near the tumor and then blocking the blood flow to allow a higher concentration of the drug to reach the tumor for a longer period of time. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving chemoembolization together with sorafenib tosylate is more effective than chemoembolization alone in treating patients with liver cancer.
NCT01017640 ↗	Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors	Completed	National Cancer Institute (NCI)	Phase 1	2009-10-01	This phase I trial studies the side effects and best dose of veliparib when given with or without mitomycin C in treating patients with solid tumors that have spread to other places in the body, cannot be removed by surgery or have come back. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with mitomycin C may kill more tumor cells.
NCT02891447 ↗	Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer	Active, not recruiting	National Cancer Institute (NCI)	Phase 2	2016-09-01	This phase II trial studies how well heated mitomycin and cisplatin during surgery work in treating patients with stomach or gastroesophageal cancer. Drugs used in chemotherapy, such as mitomycin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating a chemotherapy solution and infusing it directly into the abdomen may kill more tumor cells.

Clinical Trial Conditions for MITOZYTREX

Condition Name

Condition Name for MITOZYTREX
Intervention	Trials
Stage IIIA Bladder Cancer AJCC v8	3
Stage III Bladder Cancer AJCC v8	3
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall	2

Condition MeSH

Condition MeSH for MITOZYTREX
Intervention	Trials
Carcinoma	6
Carcinoma, Transitional Cell	3
Urinary Bladder Neoplasms	3

Clinical Trial Locations for MITOZYTREX

Trials by Country

Trials by Country for MITOZYTREX
Location	Trials
United States	163

Trials by US State

Trials by US State for MITOZYTREX
Location	Trials
Minnesota	6
Kentucky	5
Florida	5
Texas	5
California	5

Clinical Trial Progress for MITOZYTREX

Clinical Trial Phase

Clinical Trial Phase for MITOZYTREX
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	7
Phase 1	1

Clinical Trial Status

Clinical Trial Status for MITOZYTREX
Clinical Trial Phase	Trials
Recruiting	3
Not yet recruiting	3
Active, not recruiting	2

Clinical Trial Sponsors for MITOZYTREX

Sponsor Name

Sponsor Name for MITOZYTREX
Sponsor	Trials
National Cancer Institute (NCI)	10
Mayo Clinic	2
M.D. Anderson Cancer Center	1

Sponsor Type

Sponsor Type for MITOZYTREX
Sponsor	Trials
NIH	10
Other	5

Last updated: May 3, 2026

Clinical trials update, market analysis and projection for MITOZYTREX

No reliable, citable clinical-trials, regulatory, or market data is available for a drug named MITOZYTREX in the major public patent and regulatory sources typically used for oncology and pharma diligence.

What is known about “MITOZYTREX” in public regulatory and patent sources?

No traceable record is available here for:

• An approved product or an active investigational program under the name MITOZYTREX
• A clinical trial registry entry (e.g., ClinicalTrials.gov or EU CTR) under that name
• A patent family that clearly maps to a drug candidate marketed or developed as MITOZYTREX

What is the clinical-trials update for MITOZYTREX?

No complete, accurate clinical-trials status can be produced for MITOZYTREX because the underlying program cannot be identified in public clinical-trials databases under that name.

What is the market analysis for MITOZYTREX?

No market analysis can be computed because the drug’s:

• Indication(s)
• Mechanism of action
• Clinical stage and label prospects
• Competitive set cannot be identified from public sources tied to MITOZYTREX.

What is the market projection for MITOZYTREX?

No defensible projection can be produced because the drug’s:

• Target population and incidence/prevalence inputs
• Comparator set and expected uptake
• Pricing and reimbursement regime
• Clinical probability of success and timeline cannot be anchored to any identifiable MITOZYTREX program.

---

Key Takeaways

• MITOZYTREX cannot be matched to a specific, verifiable drug development program in public clinical, regulatory, or patent sources using that name.
• Without an identifiable program, clinical-trials updates, market sizing, and forecast projections cannot be produced in a way that is complete and accurate.

---

FAQs

1. Can you provide MITOZYTREX clinical trial phases, enrollment, endpoints, and timelines?
   No: the program cannot be identified in public trial registries under the name MITOZYTREX.

2. Can you list sponsors, trial sites, and results for MITOZYTREX?
   No: no traceable MITOZYTREX trial records can be verified.

3. What is the expected competitive landscape for MITOZYTREX?
   No: the drug’s indication and MOA cannot be verified for MITOZYTREX.

4. What revenue forecast range can you give for MITOZYTREX?
   No: revenue models require a defined indication, comparators, and clinical stage inputs that cannot be verified.

5. Is MITOZYTREX approved in any jurisdiction?
   No verifiable approval record is available under the name MITOZYTREX from major public sources.

---

References

[1] ClinicalTrials.gov. (n.d.). https://clinicaltrials.gov/
[2] EMA. (n.d.). European public assessment reports (EPAR). https://www.ema.europa.eu/
[3] FDA. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[4] WIPO PATENTSCOPE. (n.d.). https://patentscope.wipo.int/